Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 11, 2017

Biotronik Announces FDA Approval of MultiPole Pacing

New technology will be available on Biotronik CRT-D systems along with ProMRI

Biotronik Announces FDA Approval of MultiPole Pacing

May 11, 2017 — Biotronik announced U.S. Food and Drug Administration (FDA) approval of the company's MultiPole Pacing (MPP) technology, providing physicians with additional treatment options for heart failure patients who have been non-responsive to cardiac resynchronization therapy (CRT). MPP will be available on new Biotronik CRT defibrillator (CRT-D) systems for patients with heart failure.

Nearly 40 percent of heart failure patients are initially non-responsive to CRT. Biotronik's MPP technology addresses this challenge by enabling the left ventricle to be paced twice per cardiac cycle. Uniquely, these paces can be either sequential or simultaneous, allowing for greater customization of therapy to meet specific patient needs. The company’s CRT-D systems include MPP and feature ProMRI technology, providing patients with access to critical diagnostic imaging scans as needed. These devices are also equipped with MRI AutoDetect, a dedicated sensor that detects the magnetic resonance imaging (MRI) environment, converts the patient's device to MRI mode, and then automatically returns to its permanent program when the scan is complete.

"MultiPole Pacing is an important technology that allows physicians to tailor cardiac resynchronization therapy to each patient," said Gery Tomassoni, M.D., Baptist Health, Lexington, Ky. "Heart failure is a complex condition and physicians are routinely challenged to find the ideal treatment for unique disease presentations. Adding MPP technology to other key Biotronik features creates more options for physicians to meet evolving patient needs."

Biotronik will feature MPP and other 360° CRT solutions at the 2017 Heart Rhythm Society (HRS) Annual Meeting, May 10-13 in Chicago.

For more information: www.biotronik.com

Related Content

Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Videos | Cardiac Resynchronization Therapy Devices (CRT) | May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 10, 2017
Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm...
NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment
News | Cardiac Resynchronization Therapy Devices (CRT) | April 14, 2017
The National Institute for Health and Care Excellence (NICE) recently issued medical technology guidance recommending...
Biotronik, Edora series, pacemakers, CRT-Ps
Technology | Cardiac Resynchronization Therapy Devices (CRT) | March 23, 2017
March 23, 2017 — Biotronik announced the European launch of the Edora series, its smallest series of...
Medtronic, CRT-D, REVERSE Trial analysis, cost-effectiveness, Michael R. Gold, JACC Heart Failure
News | Cardiac Resynchronization Therapy Devices (CRT) | March 07, 2017
March 7, 2017 — Medtronic plc recently announced an economic analysis of five-year data showing that patients with mi
Overlay Init